Ten Years and Counting: Moving Leucine-Rich Repeat Kinase 2 Inhibitors to the Clinic

The burden that Parkinson's disease (PD) exacts on the population continues to increase year after year. Though refinement of symptomatic treatments continues at a reasonable pace, no accepted therapies are available to slow or prevent disease progression. The leucine-rich repeat kinase 2 (LRRK...

Descripción completa

Detalles Bibliográficos
Autor principal: West, Andrew B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Scientific Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318704/
https://www.ncbi.nlm.nih.gov/pubmed/25448543
http://dx.doi.org/10.1002/mds.26075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318704/
https://www.ncbi.nlm.nih.gov/pubmed/25448543
http://dx.doi.org/10.1002/mds.26075

Ejemplares similares